trap5b  (Quidel)

Journal: Communications Medicine

Article Title: Exhaled breath metabolites reveal postmenopausal gut-bone cross-talk and non-invasive markers for osteoporosis

doi: 10.1038/s43856-024-00723-4

Figure Lengend Snippet: Demography, lifestyle, clinical status and ongoing therapy

Article Snippet: To this purpose, assays for BAP and TRAP5b were purchased from IDS (Immunodiagnostic Systems Limited, Boldon Colliery, UK), the ones used for quantification of sclerostin, soluble α-Klotho and iFGF23 were obtained from TECO Medical Group (Sissach, Swiss), IBL (Immuno-Biological Laboratories, Minneapolis, USA) and Kainos Laboratories (Tokyo, Japan), respectively.

Techniques: Biomarker Discovery, Infection

Journal: Communications Medicine

Article Title: Exhaled breath metabolites reveal postmenopausal gut-bone cross-talk and non-invasive markers for osteoporosis

doi: 10.1038/s43856-024-00723-4

Figure Lengend Snippet: a Receiver operating characteristic (ROC) analysis of subject’s biological age, grip strength, bone- (BAP, TRAP5b, sclerostin, FGF23 and klotho) and exhaled breath (dimethyl sulfide/DMS, allyl-methyl sulfide, butanethiol and butyric acid) markers within the discovery cohort. Area under the curve (AUC) and quantitative cutoff values are calculated with statistical significance ( p < 0.05). Amongst all parameters, exhaled alveolar DMS concentrations yielded a high AUC value of 0.86 (bounds: 0.790 – 0.931 at 95% CI, standard error of 0.037 and asymptotic p < 0.0001 under non-parametric assumptions). b Scatter-plot showing green, yellow and red colored dots for subjects with normal, at risk and at high-risk BMD values, respectively. Discovery cohort derived DMS cutoff of 15.88 ppbV is applied (horizontal black arrow) to predicted the subjects with BMD at high-risk of osteoporosis within the independent validation cohort including seasonal follow-ups. Darker and lighter dots of each color represent the summer and winter values, respectively from each subject. Applied DMS cutoff resulted in >91% test accuracy (sensitivity of 91.7% and specificity of 91.3%) for osteoporosis risk classification including seasonal follow-ups. c ROC curve confirming high classification accuracy (AUC = 0.97, bounds: 0.94 – 0.99) of exhaled DMS in independent validation cohort including seasonal follow-ups.

Article Snippet: To this purpose, assays for BAP and TRAP5b were purchased from IDS (Immunodiagnostic Systems Limited, Boldon Colliery, UK), the ones used for quantification of sclerostin, soluble α-Klotho and iFGF23 were obtained from TECO Medical Group (Sissach, Swiss), IBL (Immuno-Biological Laboratories, Minneapolis, USA) and Kainos Laboratories (Tokyo, Japan), respectively.

Techniques: Derivative Assay, Biomarker Discovery

Journal: Journal of Bone Metabolism

Article Title: Clinical Utility of Bone Turnover Markers in Chronic Kidney Disease

doi: 10.11005/jbm.24.789

Figure Lengend Snippet: Diagnostic accuracy for parathyroid hormone and bone turnover markers in diagnosing low vs. non-low bone turnover renal osteodystrophy in chronic kidney disease 4–5D in the last decade

Article Snippet: TRAP5b , Lima et al. (2019) [ ] , G2-5D (N=104) , Quidel (unspecified U/L) , 4.3 , 0.68 (0.53–0.83) , 65 , 76 , , .

Techniques: Diagnostic Assay

Journal: Journal of Bone Metabolism

Article Title: Clinical Utility of Bone Turnover Markers in Chronic Kidney Disease

doi: 10.11005/jbm.24.789

Figure Lengend Snippet: Diagnostic accuracy for parathyroid hormone and bone turnover markers in diagnosing high vs. non-high bone turnover renal osteodystrophy in chronic kidney disease 4–5D in the last decade

Article Snippet: TRAP5b , Lima et al. (2019) [ ] , G2-5D (N=104) , Quidel (unspecified U/L) , 4.3 , 0.68 (0.53–0.83) , 65 , 76 , , .

Techniques: Diagnostic Assay